Brief: Erasca Presents Promising Initial Phase 1B Dose Escalation Data From Flagshp-1 For Eras-601 Plus Cetuximab In Patients With Advanced Solid Tumors At 2023 AACR Annual Meeting
18/04/2023 14:01
April 18 (Reuters) - Erasca Inc ERAS.O :
* ERASCA PRESENTS PROMISING INITIAL PHASE 1B DOSE ESCALATION
DATA
FROM FLAGSHP-1 FOR ERAS-601 PLUS CETUXIMAB IN PATIENTS WITH
ADVANCED SOLID TUMORS AT 2023 AACR ANNUAL MEETING
* ERASCA INC - COMBINATION WAS WELL-TOLERATED; SUPPORTS
'THREE
WEEKS ON, ONE WEEK OFF' DOSING OF ERAS-601
* ERASCA INC - DOSE EXPANSION DATA IN HPV-NEGATIVE HNSCC
EXPECTED
IN H1 2024
Source text for Eikon: ID:nGNX8YMXwB
Further company coverage: ERAS.O